Clinical trials: Cancer of the Esophagus
Epiphora Due to Insufficient Drainage, Left Side, Epiphora Due to Insufficient Drainage, Right Side
Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis
On the basis of minimally invasive Ivor Lewis operation for the treatment of lower thoracic esophageal cancer or esophageal gastric junction cancer, the purpose of this study is to compare the probability of anastomotic leakage…
- Trial name
- NCT05812495
- Testing
- Esophagogastric Side to Side Anastomosis, Esophagogastric End to Side Anastomosis
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer
Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy
This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.
- Trial name
- EASOPCWAAC (NCT06586242)
- Testing
- Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatin
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Xijing Hospital
Esophageal Squamous Cell Carcinoma, Chemoradiation
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
This clinical trial has two stages: phase II and phase III. Eligible patients will be randomized 1:1 to the two arms: paclitaxel plus cisplatin and cisplatin plus 5-fluorouracil.
- Trial name
- NCT03623737
- Testing
- neoadjuvant chemoradiation
- Where
- Taiwan
- Volunteers
- 248 people
- Sponsor
- National Taiwan University Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
This is a phase 3, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of tislelizumab (BGB-A317) versus placebo in combination with chemoradiotherapy in participants with localized esophageal…
- Trial name
- NCT03957590
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 33 sites in China
- Volunteers
- 370 people
- Sponsor
- BeiGene
Esophagus Cancer
The Efficacy and Safety of Caffeic Acid for Esophageal Cancer
Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer.
- Trial name
- CAEC (NCT03070262)
- Testing
- CA
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Neoplasms
Influence of Esophageal Washout on Local Carcinoma Recurrence After Curative Resection
The LOCARE-Trial is an investigator initiated, randomized-controlled trial with two parallel arms (n=60 each) and investigates the influence of esophageal washout on long-term outcomes in patients undergoing elective esophageal…
- Trial name
- LOCARE (NCT02676791)
- Testing
- Povidone-Iodine
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Technische Universität Dresden
Oesophageal Cancer
Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)
This is an observational trial that will look at patients undergoing endoscopic ultrasound (EUS) in patients with oesophageal cancer and to determine the proportion of cases in which EUS changes disease management in these…
- Trial name
- VALUE (NCT06440174)
- Testing
- endoscopic ultrasound
- Where
- 14 sites in United Kingdom
- Volunteers
- 160 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Esophageal Cancer (EC)
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)
Chemotherapy combined with PD-1 inhibitor immunotherapy is the standard treatment for advanced esophageal squamous cell carcinoma (ESCC), yet patient prognosis remains unsatisfactory, with a median PFS of only about 6 months and…
- Trial name
- NCT07863141
- Testing
- anlotinib + PD-1 inhibitor, PD-1 inhibitor
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer, Gastric Cancer
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
The main purpose of this study is to see whether the combination of selinexor (KPT-330) and irinotecan can help people with esophageal or stomach cancer.
- Trial name
- NCT02283359
- Testing
- Selinexor, Irinotecan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer, Squamous Cell Carcinoma
Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases
There is no world-wide consensus on the oncological benefit versus increased morbidity associated with three field lymphadenectomy in patients with esophageal cancer and cervical lymph node metastases.
- Conditions
- Cancer, Squamous Cell Carcinoma, Adenocarcinoma, Malignancy
- Trial name
- Node (NCT02426879)
- Testing
- esophagectomy with three-field lymphnode dissection
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- UMC Utrecht
Solid Tumors
Investigator Initiated Phase 1 Study of TBI-1301
Following pre-treatment with cyclophosphamide and/or fludarabine, NY-ESO-1-specific TCR gene transduced T lymphocytes are transferred to the patients with NY-ESO-1-expressing solid tumors.
- Trial name
- NCT02366546
- Testing
- TBI-1301, Cyclophosphamide, Fludarabine
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Mie University
Esophageal Cancer
Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and capecitabine, work in different ways to kill tumor cells or stop them from growing. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00509561
- Testing
- cetuximab, capecitabine, cisplatin
- Where
- 55 sites in United Kingdom
- Volunteers
- 259 people
- Sponsor
- Wales Cancer Trials Unit
Barrett's Esophagus
Confocal Laser Endomicroscopy vs Conventional Histology for the Identification of Intestinal Metaplasia
Real-time Diagnosis of Barrett's Esophagus: Comparing Confocal Laser Endomicroscopy with Conventional Histology for the Identification of Specialized Intestinal Metaplasia
- Trial name
- NCT02632682
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Minnesota Institute for Minimally Invasive Surgery
Barrett Esophagus
Non-endoscopic Brushing of the Esophagus Using a Non-endoscopic Inflatable Balloon of the Esophagus in Screening for Barrett Esophagus
This pilot clinical trial studies non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus in screening for Barrett esophagus, a condition where the lining of the esophagus has changed…
- Trial name
- NCT02451124
- Testing
- non-endoscopic inflatable balloon for the esophagus, Questionnaire Administration, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Esophageal Cancer
The Diagnostic Value of Nitrogen Element (N) in Esophagus Cancer
The purpose of this study is to determine the diagnostic value of various nitrogen components in oral gas for esophagus cancer (ESCA) .
- Trial name
- NCT05494359
- Testing
- The nitrogen isotope
- Where
- 3 sites in China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Gastro-Intestinal Cancer
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of…
- Trial name
- NCT05332002
- Testing
- Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Rutgers, The State University of New Jersey
Barrett Esophagus, Esophagus
TECR & ECM Placement for Esophageal High Grade Dysplasia
This study will test the safety and effectiveness of esophageal transoral endoscopic circumferential resection (TECR) using an extracellular matrix (ECM) placement to treat Barrett's esophagus in patients with high-grade…
- Conditions
- Barrett Esophagus, Esophagus, High Grade Dysplasia
- Trial name
- NCT02396745
- Testing
- Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Esophageal Cancer, Gastric Cancer
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the…
- Conditions
- Esophageal Cancer, Gastric Cancer, GE Junction Cancer
- Trial name
- NCT00165464
- Testing
- Taxotere, Cisplatin, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Esophageal Neoplasms
Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China
In this study, data of esophageal cancer patients undergoing definitive radiotherapy in 14 institutions from various provinces in China were evaluated to help strengthen confidence in anti-cancer, including rehabilitation…
- Trial name
- NCT05194371
- Testing
- definitive radiotherapy or definitive chemoradiotherapy
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Chinese Academy of Medical Sciences